Research led by the LMB’s Anne Bertolotti has discovered a selective inhibitor of a phosphatase enzyme that could prevent protein misfolding diseases. The scientists showed that the new molecule, dubbed Sephin1, countered the effects of aggregating proteins in mouse models of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease, and might do so for other neurodegenerative disorders. […]
LMB In The News
Mechanism-based therapeutics of common human neurodegenerative diseases
The LMB and the Department of Clinical Neurosciences have announced an initiative in mechanism-based therapeutics of common human neurodegenerative diseases. This initiative, developed by Michel Goedert and Alastair Compston, aims to identify core mechanisms of protein aggregation and spreading in neurodegeneration, and to apply that knowledge to study putative new therapies. More…
First pictures of the mitoribosome taken
Researchers, including a team from the LMB, have obtained structures of complete ribosomes from mammalian mitochondria at near-atomic resolution for the first time. More…
Body clock expert talks to students
Michael Hastings delivers sixth form lecture at King William’s College, Isle of Man, on his research into circadian rhythms and biological clocks. This article is no longer available from the source website: Isle of Man Today 1 April 2015
Image of the Week: Structure of the dynactin complex
The structure of the dynactin complex, solved by Andrew Carter’s group at the LMB, is the cover story on this week’s Science and is the Wellcome Trust’s Image of the week. The picture shows a model of the dynein/dynactin protein machine that moves cargo around the cell, that was determined using electron cryo-microscopy. This article […]
David Komander part of collaborative consortium in the field of deubiquitinating enzymes.
FORMA Therapeutics and Cancer Research Technology, Ltd (CRT) have announced the formation of two new virtual Asset Discovery and Development Companies (ADDCos) to represent the collective efforts of the consortium in the field of deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of […]